FX-201 is under clinical development by Pacira BioSciences and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect FX-201’s likelihood of approval (LoA) and phase transition for Osteoarthritis took place on 13 May 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their FX-201 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

FX-201 overview

FX-201 is under development for the treatment of osteoarthritis of knee. The drug candidate is a gene therapy. It is administered by intra-articular route. The drug candidate comprises of helper-dependent adenoviral vectors delivering interleukin-1 receptor antagonist (hIL-1Ra).

Pacira BioSciences overview

Pacira BioSciences (Pacira), formerly Pacira Pharmaceuticals Inc, provides non-opioid pain management and regenerative health solutions. The company develops drugs based on its proprietary DepoFoam drug delivery technology. Its lead product candidate, Exparel (bupivacaine liposome injectable suspension) is an amide-type local anesthetic administered at the time of surgery to control pain and eliminate the use of opioids for acute postsurgical pain. Its other products include iovera, a non-opioid treatment intended to block pain, and relieve pain and symptoms related to osteoarthritis of the knee; among others. Its products are essentially used by hospitals, doctors and ambulatory surgery centers. The company sells products through co-promotion agreements and supply agreements with other pharmaceutical companies. The company has operations in the US and the UK. Pacira is headquartered in Tampa, Florida, the US.

Quick View FX-201 LOA Data

Report Segments
  • Innovator
Drug Name
  • FX-201
Administration Pathway
  • Intraarticular
Therapeutic Areas
  • Musculoskeletal Disorders
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.